Keyphrases
Hematological Malignancies
100%
Combination Therapy
100%
Myelodysplastic Syndrome
100%
DNA Methyltransferase Inhibitor
100%
Acute Myeloid Leukemia
71%
Response Rate
28%
Duration of Response
28%
Disease States
14%
Rapid Evolution
14%
Methylation
14%
Less Toxic
14%
Adverse Events
14%
Pharmacodynamic Interactions
14%
Complete Response
14%
Cytotoxic Effect
14%
Cytotoxic Chemotherapy
14%
Partial Response
14%
Epigenetic Modification
14%
Monotherapy
14%
New Therapies
14%
Complete Remission
14%
Biological Mechanisms
14%
Dosing Regimen
14%
Cytotoxic Therapy
14%
Optimal Dosing
14%
Combination Regimen
14%
Prolonged Survival
14%
Biologic Pathways
14%
Azacitidine
14%
Quality of Life Issues
14%
Myeloid Malignancies
14%
Decitabine
14%
Transcriptional Dysregulation
14%
Complementary Mechanism
14%
Incremental Improvement
14%
Response Quality
14%
Overall Failure
14%
Pharmacology, Toxicology and Pharmaceutical Science
Combination Therapy
100%
Myelodysplastic Syndrome
100%
Hematologic Malignancy
100%
DNA Methyltransferase Inhibitor
100%
Acute Myeloid Leukemia
71%
Cytotoxic Chemotherapy
28%
Disease
14%
Adverse Event
14%
Pharmacodynamics
14%
Remission
14%
Monotherapy
14%
Azacitidine
14%
Decitabine
14%